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Background: Randomized controlled trials focusing on the effects of antidepressant 
treatment in cardiac patients have found modest effects on depressive symptoms but not on 
cardiac outcomes. A secondary analysis was conducted on data from the Enhancing Recovery 
in Coronary Heart Disease trial to assess whether changes  in somatic or cognitive depressive 
symptoms following acute MI predicted event-free survival and whether the results differed 
per treatment arm (cognitive behavior therapy or care as usual). Methods: Patients who met 
depression criteria and completed the 6th month depression assessment (n=1,254) were 
included in this study. Measurements included demographic and clinical data and the Beck 
Depression Inventory at baseline and 6 months. The primary endpoint was a composite of 
recurrent MI and mortality over 2.4 years (standard deviation=0.9 years). Results: Positive 
changes (per 1 point increase) in somatic depressive symptoms (HR: 0.95; 95% CI: 0.92-0.98; 
p=0.001) but not in cognitive depressive symptoms (HR: 0.98; 95% CI: 0.96-1.01; p=0.19) 
were related to a reduced risk of recurrent MI and mortality after adjustment for baseline 
depression scores. There was a trend for an interaction effect between changes in somatic 
depressive symptoms and the intervention (p=0.08). After controlling for demographic and 
clinical variables, the association between changes in somatic depressive symptoms and 
event-free survival remained significant in the intervention arm (HR: 0.93; 95% CI: 0.88-0.98; 
p=0.01) only. Limitations: Secondary analyses. Conclusions: Changes in somatic 
depressive symptoms, and not cognitive symptoms, were related to improved outcomes in the 
intervention arm, independent of demographic and clinical variables.  
 






Depression is associated with morbidity and mortality in patients with coronary heart disease 
(CHD) and this association appears to be independent from medical variables, including 
measures of cardiac disease severity [Barth et al., 2004; Meijer et al., 2011]. Randomized 
controlled trials focusing on the effects of antidepressant treatment in cardiac patients have 
found modest effects on depressive symptoms but not on cardiac outcomes [Glassman et al., 
2002; Berkman et al., 2003; van Melle et al., 2007]. Further analyses of these studies revealed 
that patients who did not respond to antidepressant treatment were at increased risk of 
adverse outcomes [Glassman et al., 2009; Carney et al., 2004; de Jonge et al., 2007]. Several 
recent studies suggest that somatic symptoms of depression (e.g. fatigue, sleep problems), but 
not cognitive symptoms (e.g. shame, guilt) are related to adverse cardiac prognosis in patients 
with myocardial infarction (MI) [de Jonge et al., 2006; Martens et al., 2010; Smolderen et al., 
2009]. Although the association between somatic symptoms of depression and adverse 
prognosis was partly confounded by somatic health status, somatic symptoms of depression 
remained predictive of cardiac outcomes after adjustment for measures of disease severity [de 
Jonge et al., 2006; Martens et al., 2010]. No previous studies have focused on the changes in 
cognitive and somatic depressive symptoms after depression treatment and their potentially 
differential associations with event-free survival.  
  
This is a secondary analysis of data from the Enhancing Recovery in Coronary Heart Disease 
(ENRICHD) trial. We assessed whether somatic and cognitive depressive symptoms 
improved after cognitive behavior therapy (CBT) and whether changes in somatic or 
cognitive depressive symptoms following acute MI were related to event-free survival. We 
also assessed whether these associations differed by treatment arm since an earlier study 
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based on the ENRICHD trial showed that intervention patients whose depression did not 
improve were at higher risk for late mortality than were patients who responded to treatment 
[Carney et al., 2004]. We hypothesized that positive changes in somatic symptoms of 




Participants were patients recruited within 28 days following an acute MI who met 
ENRICHD-modified Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) [American Psychiatric Association, 1994] criteria for major depressive disorder, 
minor depressive disorder with a history of major depressive disorder, or dysthymia using the 
Depression Interview and Structured Hamilton (DISH) [Freedland et al., 2002]. Under these 
criteria, patients were eligible if depressive symptoms had been present for at least 7 days, 
provided patients had a history of major depression [The ENRICHD Investigators, 2000; 
Berkman et al., 2003]. Patients admitted between October 1996 and November 1999 to 
coronary care units at eight ENRICHD clinical trial sites for an MI were screened for 
eligibility. MI was documented by cardiac enzymes and by chest pain compatible with acute 
MI, characteristic evolutionary ST-T changes, or new Q waves. Details of the methods and 
design of the ENRICHD clinical trial are available elsewhere [Berkman et al., 2003; The 
ENRICHD Investigators, 2000]. Briefly, patients were excluded if they: 
 
1. had other life-threatening medical illnesses, cognitive impairment, other major 
psychiatric disorders, or were at imminent risk of suicide; 
2. were too ill or logistically unable to participate; 
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3. had been taking a non-study antidepressant for less than 21 days; or 
4. were exempted by their cardiologist from participating in the study. 
 
For the present analyses, patients included in ENRICHD with low perceived social support 
but no depression were excluded, as were patients who had a recurrent MI or died before the 




Depressive symptoms were measured with the Beck Depression Inventory (BDI), a 21-item 
self-report measure developed to assess the presence and severity of depressive symptoms 
[Beck et al., 1961]. Each item is rated on a 0-3 scale with higher scores reflecting greater 
severity. The BDI is a valid and reliable measure of depressive symptoms in cardiac patients 
[Davidson et al., 2006]. For the present study, we used the BDI at the time of randomization 
and at 6 months post-randomization to calculate difference scores comparable to the time 
frame of the active treatment arm. Depressive symptoms were defined as cognitive or somatic 
using the original division proposed by Beck and Steer [Beck et al., 1987]. Therefore, the 
items concerning sadness, pessimism, sense of failure, dissatisfaction, guilt, punishment, self-
dislike, self-accusations, suicidal ideas, crying, irritability, social withdrawal, and 
indecisiveness were summed to obtain scores for the cognitive depressive dimension and the 
items concerning body image change, work difficulty, insomnia, fatigue, loss of appetite, 
weight loss, somatic preoccupation, and loss of libido were summed to obtain scores for the 
somatic depressive dimension. This division was chosen because in recent studies in patients 
with CHD, items divergently loaded on the somatic and cognitive dimension [de Jonge et al., 
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2006; Martens et al., 2010; Roest et al., 2011].  However, a 2 factor solution resembling the 
original division is found in most cases. Further, significant change in somatic depressive 
symptoms was defined as a standardized effect size (Cohen’s d)  ≥0.5, which is widely 
accepted as representing a clinically meaningful improvement in depression [Denollet J and 
Brutsaert, 2001]. We assessed whether patients who significantly improved were at decreased 
risk of adverse outcomes and we compared baseline characteristics of patients who 
significantly improved with characteristics of patients who did not improve.  
Design and treatment 
After written informed consent was obtained, the participants were randomly assigned by an 
automated system located at the ENRICHD coordinating center within 28 days of their index 
MI, to receive either the intervention or usual care. Both groups received the American Heart 
Association’s Active PartnershipTM  health education booklet. The usual care patients 
received no further contact from study personnel except for follow-up.  
The intervention consisted of CBT and was guided by two standard CBT manuals [Beck, 
Rush, Shaw, Emery, 1979; Beck, 1995]. The Beck Institute for Cognitive Therapy and 
Research provided the training and quality control for the intervention. The therapists were 
supervised by clinical investigators at each site and by Beck Institute Personnel. The 
intervention, training and quality control procedures are described in detail elsewhere [The 
ENRICHD Investigators, 2001]. Participants randomized to the intervention arm who were 
severely depressed (Hamilton Rating Scale for Depression score >24) at enrolment or who 
did not show at least a 50% reduction in BDI scores after five weeks of CBT were referred to 
a study psychiatrist for concurrent pharmacotherapy. For these patients, unless 
contraindicated, sertraline was initiated at 50 mg per day. Patients who were unable to 
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tolerate or who were unresponsive to sertraline were switched to an alternative antidepressant. 
The maximum duration of treatment was 6 months of CBT and 12 months of sertraline.  
Endpoints 
The primary endpoint for the present analysis was a composite of all-cause mortality and 
recurrent MI, consistent with the primary endpoint of the ENRICHD randomized trial 
[Berkman et al., 2003]. All-cause mortality was a secondary endpoint. These endpoints were 
ascertained by follow-up assessments (including a medical history, physical examination and 
a resting electrocardiograph) and phone calls, routine hospital surveillance, and contacts with 
the patient’s physician. Since this study focused on the effects of changes in depressive 
symptoms on event-free survival, only deaths and MIs that occurred after the assessment of 
depression outcomes (6 months) were taken into account, which is consistent with previous 
studies [Carney et al., 2004; de Jonge et al., 2007]. The mean follow-up period was 2.4 years 
(standard deviation [SD]=0.9 years).  
 
Statistical analysis 
Discrete and continuous variables were compared with the chi-square test and the 
independent-samples t-test. Changes in somatic and cognitive depressive symptoms were 
calculated by subtracting the 6 month sum scores from the baseline sum scores. Cox 
regression analyses were used to model the covariate-adjusted effect of changes in cognitive 
and somatic depressive symptoms between enrollment and the 6-month follow-up on event-
free survival beyond 6 months. The hazard ratios (HR) represent the change in risk associated 
with a 1-point increase in the respective depressive symptom dimension. Further, we assessed 
whether there was an interaction effect between treatment and changes in somatic or 
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cognitive depressive symptoms concerning the endpoints. To control for the possible adverse 
effects of baseline depressive symptoms, the hazard estimates of changes in depressive 
symptoms were adjusted for these baseline scores as is consistent with other studies [Carney 
et al., 2004].  
Multivariable analyses were adjusted for demographic and medical factors that predicted 
mortality and recurrent MI in the ENRICHD trial [Jaffe et al., 2006], including age, diabetes, 
renal insufficiency, left ventricular ejection fraction (LVEF), creatinine, history of pulmonary 
disease, history of congestive heart failure (CHF), prior transient ischemic attack (TIA) or 
stroke, coronary artery bypass graft surgery (CABG) after index MI, and use of non-
angiotensin converting enzyme vasodilators. Missing scores on the covariates were imputed 
using a multiple imputation procedure with 50 iterations. SAS software 9.1.3 was used to 
perform the multiple imputation and SPSS version 17.0 and STATA version 8 were used for 
the statistical analyses. All statistical tests were 2-tailed, with p<0.05 denoting significance.  
Results 
 
Eleven patients had a missing baseline measurement on the BDI and 341 patients did not 
complete the 6th month depression assessment, leaving 1254 participants, 654 in the 
intervention and 600 in the control group, for further analyses. Forty-six patients met criteria 
for dysthymia, 555 for minor depression and 653 for major depression. Patients who did not 
complete the 6th month depression assessment were more likely to be in the control group 
(p=0.01) but there were no differences concerning baseline depression severity (p=0.77), age 
(p=0.87), and gender (p=0.07). During the follow-up period, which started after the 6th month 
depression assessment, 179 patients died or had a recurrent MI. Table 1 shows the 




Changes in depressive symptoms  
At baseline mean BDI score was 17.7 (SD=7.8) for the total group and 17.5 (SD=8.0) for the 
intervention and 17.9 (SD=7.6) for the care as usual group.  At 6 months follow-up the mean 
score was 10.3 (SD=8.9) for the total group and 8.8 (SD=8.4) for the intervention and 12.0 
(SD=9.2) for the care as usual group. Patients had a mean positive change of 4.0 (SD=6.0) in 
cognitive depressive symptoms and a positive change of 3.3 (SD=4.5) in somatic depressive 
symptoms from baseline to the 6 month follow-up. The mean change was significantly larger 
for the intervention group for both the cognitive symptoms (4.7 [SD=6.1] versus 3.2 
[SD=5.9]; p<.001) and the somatic symptoms, (mean=4.0 [SD=4.4] versus 2.7 [SD=4.5]; 
p<.001) compared to the care as usual group.  
 
 Changes in depressive symptoms as predictors of event-free survival 
Baseline cognitive depressive symptoms (HR: 1.00; 95% confidence interval (CI): 0.97-1.03; 
p=0.99) were not related to mortality and recurrent MI at follow-up, while baseline somatic 
depressive symptoms were (HR: 1.05; 95% CI: 1.01-1.09; p=0.01). After adjustment for 
baseline cognitive depressive symptom scores, changes in cognitive depressive symptoms 
were not associated with improved outcome (HR: 0.98; 95% CI: 0.96-1.01; p=0.19). 
However, positive changes in somatic depressive symptom scores were significantly related 
to event-free survival after controlling for baseline somatic depressive scores (HR: 0.95; 95% 
CI: 0.92-0.98; p=0.001). There was no interaction effect between changes in cognitive 
symptoms and treatment arm (p=0.25) but there was a trend for an interaction effect between 
changes in somatic depressive symptoms and the intervention (p=0.08), indicating that the 
effect of changes in somatic depressive symptoms on prognosis tended to differ by treatment 
group. We further assessed the association between changes in somatic depressive symptoms 
and adverse outcomes in the two treatment groups. After adjustment for demographic and 
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medical covariates, change in somatic depressive symptoms was not related to prognosis in 
the control group (HR: 1.00; 95% CI: 0.95-1.05; p=0.96), but was an independent predictor 
of event-free survival in the intervention group (HR: 0.93; 95% CI: 0.88-0.98; p=0.01) (table 
2). Because antidepressant use differed between the intervention and control group, we 
additionally adjusted for use of selective serotonin reuptake inhibitors, but this did not change 
the association between changes in somatic depressive symptoms and event-free survival in 
the intervention group (HR: 0.92; 95% CI: 0.87-0.97; p=0.004).  
We found similar results with respect to the secondary endpoint, all-cause mortality. There 
was a significant interaction effect between changes in somatic depressive symptoms and the 
intervention concerning the secondary endpoint (p=0.02). Change in somatic depressive 
symptoms was an independent predictor of all-cause mortality in the intervention group (HR: 
0.91; 95% CI: 0.85-0.97; p=0.004) but not in the care as usual group (HR: 1.02; 95% CI: 
0.96-1.08; p=0.55) after adjustment for baseline somatic depressive symptoms scores, and 
demographic and medical covariates. 
 
Substantial improvement in somatic depressive symptoms 
Patients whose somatic depressive symptom scores improved substantially after CBT 
(standardized effect size ≥0.5) had a mean positive change of 6.0 (SD=3.2) in somatic 
symptoms compared with a mean negative change of 1.3 (SD=2.7) for patients who did not 
improve following CBT.  Patients whose symptoms improved were at decreased risk of 
adverse outcomes compared with patients who did not improve. Although this association 
was not significant for the primary composite endpoint consisting of all-cause mortality or 
recurrent MI, (HR: 0.70; 95% CI: 0.44-1.09; p=0.11), it was significant for the secondary 
endpoint, all-cause mortality, (HR: 0.52; 95% CI: 0.29-0.94; p=0.03) (figure 1). The 
association between improvement in somatic depressive symptoms and all-cause mortality in 
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the intervention group remained marginally significant after adjustment for demographic and 
medical variables (HR: 0.55; 95% CI: 0.30-1.01; p=0.05). 
 
Comparison of demographic and medical characteristics between groups 
Demographic and medical characteristics of patients whose somatic depressive symptom 
scores improved after CBT were compared with patients whose somatic symptoms did not 
improve during treatment. Patients who did not improve were more likely to be treated with 
antidepressants during the intervention (p<.001), which is explained by the design of the 
intervention, as only patients who were severely depressed at baseline or who did not respond 
quickly enough to the CBT received antidepressant medication. Further, patients who 
improved during the intervention were more likely to be female (p=0.01). Finally, patients 
who did not improve during treatment were more likely to have a history of transient 
ischemic attack (TIA) or stroke (p=0.05) and to have high cholesterol (p=0.05) (table 3) than 
those whose somatic depressive symptoms improved.    
 
Discussion 
This study is the first to assess changes in somatic and cognitive depressive symptoms after 
depression treatment and their association with event-free survival in depressed MI patients. 
Patients who received antidepressant treatment, namely CBT and concurrent antidepressant 
medication when necessary, had larger changes in cognitive and somatic depressive 
symptoms compared with patients in the usual care group. Changes in cognitive depressive 
symptoms were not related to event-free survival. Conversely, changes in somatic depressive 
symptoms were related to improved outcomes in the intervention group, independent of 
demographic and clinical variables, including disease severity and use of selective serotonin 




Earlier studies found that somatic depressive symptoms and not cognitive depressive 
symptoms were independently associated with adverse outcomes in patients following an 
acute MI [de Jonge et al., 2006; Martens et al., 2010; Smolderen et al., 2009] or acute 
coronary syndrome [Roest et al., 2011], although not consistently [Frasure-Smith and 
Lespérance, 2003]. Somatic depressive symptoms were also more strongly associated with 
adverse outcomes in patients with myocardial ischemia [Linke et al., 2009], heart failure 
[Schiffer et al., 2009], and stable CHD [Hoen et al., 2010], although a study in patients 
treated with CABG surgery found that cognitive depressive symptoms were predictive of 
cardiac mortality and somatic depressive symptoms were not [Connerney et al., 2010]. The 
results of the current study add significantly to our understanding of the relationship between 
treatment for depression and cardiac outcomes in patients with heart disease and suggest that 
trials aiming to improve cardiac prognosis in depressed MI patients must improve the somatic 
depressive symptoms in order to improve survival. Although other studies have suggested 
this possibility [Bekke-Hansen et al., 2012], our study is the first to actually show that 
improvement in somatic depressive symptoms following CBT in depressed MI patients is 
related to improved cardiac prognosis.   
 
Changes in somatic depressive symptoms were associated with improved outcomes in the 
intervention group only. Although the changes were larger for the intervention group, the 
control group also showed positive changes in somatic depressive symptoms suggesting that 
size of the symptom reduction does not fully explain the differential relationship between 
improvement in somatic depressive symptoms and event-free survival for the two groups. 
There may be several other reasons why changes in somatic symptoms were associated with 
event-free survival only in the intervention group. First, the association between changes in 
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somatic depressive symptoms with event-free survival might be caused by specific effects of 
the therapy, for example if behavioral activation [The ENRICHD Investigators, 2001] 
improved feelings of fatigue and sleeping problems. Since the patients who failed to improve 
in the intervention arm did so despite intensive treatment, a second explanation is that the 
association between changes in somatic depressive symptoms with event-free survival is the 
result of the presence of a treatment-resistant form of depression [Carney et al., 2004; de 
Jonge et al,. 2007; Carney and Freedland, 2009]. This subtype of depression might be 
characterized by persistent somatic depressive symptoms associated with a high risk for 
mortality. A recent secondary analysis of the ENRICHD clinical trial data showed that 
somatic depressive symptoms at 12 months post-MI predicted mortality, while baseline 
somatic depressive symptoms did not [Bekke-Hansen et al., 2012]. Also, residual symptoms 
after depression treatment appeared to be more often somatic, namely lack of energy and 
sleeping problems [Conradi et al., 2010] suggesting that persistent somatic depressive 
symptoms might be an indication of recurrent or chronic depression. Therefore, in this study, 
it is possible that the intervention identified patients with a high risk subtype of depression 
unresponsive to standard antidepressant treatment [Carney and Freedland, 2009]. How this 
subgroup can be further specified remains unclear, although there are several propositions. 
First, patients who do not respond to antidepressant medication are more likely to have 
elevated levels of inflammation [Lanquillon et al., 2000]. Since inflammatory processes have 
been associated with recurrent cardiac events [Pearson et al., 2003] inflammation is a 
potential mechanism linking poor treatment response to standard antidepressant treatment 
with adverse cardiac outcomes [Carney and Freedland, 2009]. Another factor related to non-
response to antidepressant treatment is obstructive sleep apnea.  A study with patients with 
CHD found that patients with comorbid sleep apnea were less likely to respond to 
antidepressant medication as compared to patients without sleep apnea [Roest et al., 2012]. 
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Treatment resistant depression may be a marker of underlying sleep apnea [Roest et al., 2012] 
which is a risk factor for MI and sudden cardiac death in patients with CHD [Somers et al., 
2008].  
It has been shown repeatedly that different treatment forms (e.g. antidepressants, 
psychotherapy) improve all types of depressive symptoms [Bhar et al., 2008; Stewart et al., 
2012]. However, substantial heterogeneity exists with respect to symptom patterns of 
depression in patients with CHD [Ormel and de Jonge 2011; Poole et al., 2011]. This study 
indicates that besides treating depression as a homogeneous disorder, researchers and 
clinicians should pay special attention to somatic depressive symptoms. Close monitoring of 
changes in somatic depressive symptoms might help to improve clinical care for patients with 
MI. If patients do not respond to antidepressant treatment with significantly improved 
somatic symptoms, additional treatments (e.g. interventions for sleep disturbances) may be 
considered, even if overall depression severity improves. Also, specific cardiac risk factors 
that predict treatment resistance to antidepressant therapy in patients with CHD, e.g. sleep 
apnea, should be identified and treated, potentially leading to better cardiovascular outcomes. 
Further, future research should attempt to develop more efficacious treatments for depression 
in patients with CHD. Depression treatments that also modify cardiac risk markers in patients 
with CHD might lead to better depression and medical outcomes [Carney and Freedland 
2009]. For example, exercise therapy may offer considerable promise in patients with heart 
disease through a decrease in depressive symptoms and by simultaneously modifying 
mechanisms by which depression may be associated with increased risk, including autonomic 
nervous system and hypothalamic pituitary-adrenal axis dysfunction, and increased platelet 
activation and inflammation [Blumenthal, 2008].  
Several studies have shown that somatic depressive symptoms are related to measures of 
cardiac disease severity such as LVEF and Killip class [de Jonge et al., 2006; Martens et al., 
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2011; Roest et al., 2011]. Therefore, somatic depressive symptoms might in part be physical 
manifestations of more severe heart disease and as a result be related to adverse outcomes. 
However, in these studies the association between somatic depressive symptoms and adverse 
prognosis remained significant after adjustment for measures of cardiac disease severity [de 
Jonge et al., 2006; Martens et al., 2011; Roest et al., 2011]. Also in the current study the 
association between changes in somatic depressive symptoms with event-free survival 
remained significant after adjustment for established predictors of recurrent MI and mortality 
following MI, including LVEF, previous MI and comorbid diseases. Also, patients whose 
somatic depressive symptoms did not improve did not significantly differ on demographic 
and clinical cardiac risk factors compared with patients whose depressive symptoms 
improved, other than that patients who did not improve were more likely to be male and have 
high cholesterol levels. Nevertheless, although affecting only a small group of patients, those 
whose somatic depressive symptoms did not improve appeared to be more likely to have had 
a TIA or stroke in the past, supporting the vascular depression hypothesis which suggests that 
cerebrovascular disease can induce depressive symptoms [Alexopoulos, 2006]. Therefore, we 
cannot exclude the possibility of underlying pathophysiology explaining at least part of the 
relationship between somatic depressive symptoms and outcomes. Future research should 
carefully assess the possible confounding role of (changes in) cardiac disease severity in the 
relationship between (changes in) somatic depressive symptoms and cardiac prognosis. 
 A limitation of this study is that we did not take into account the possible effects of a 
worsening of cardiac disease during the six months of depression treatment. However, to 
minimize this possibility we excluded patients who had a recurrent MI during the time frame 
of the active treatment arm from our analyses. As a second limitation, there were a 
considerable number of patients who did not complete the 6th month depression assessment. 
Further, we defined depressive symptoms as either cognitive or somatic concordant with 
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Beck and Steer (1987). Principal component analyses have shown that, although a 2 factor 
solution is found in most cases [Martens, et al., 2010; Roest et al., 2011; Bekke-Hansen et al., 
2011], the BDI items are often not completely consistent [de Jonge et al., 2006; Martens et al., 
2010; Roest et al., 2011; Bekke-Hansen et al., 2012]. For example, a recent study on the 
ENRICHD trial including patients who were depressed or socially isolated at baseline found 
that body image change loaded on the cognitive dimension instead of the somatic dimension 
[Bekke-Hansen et al., 2012]. However, excluding body image change from the somatic 
depressive symptom dimension did not change the relationship between changes in somatic 
depressive symptoms and prognosis in this study (data not shown). Finally, since these are 
secondary, post hoc analyses of the ENRICHD trial, the results should be interpreted with 
caution. Although improvement in somatic depressive symptoms was related to event-free 
survival in the current study, future research should examine whether close monitoring of 
somatic depressive symptoms and accompanying interventions can effectively improve 
cardiac prognosis of patients. 
In summary, we found that positive changes in somatic depressive symptoms, and not 
cognitive depressive symptoms, were related to event-free survival after treatment with CBT 
in depressed patients with MI. This association was independent of demographic and clinical 
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Figure 1  
Improvement in somatic depressive symptoms following treatment and association with 
survival. 
 
 
